Treatment of advanced malignant lymphomas with bleomycin.

摘要: Bleomycin, a new antitumor agent reported to lack myelotoxicity, was administered 43 patients with disseminated refractory lymphomas. Either weekly or daily regimen used and in order minimize the possibility of pulmonary toxicity, total cumulative dose limited 5 mg/kg. In 37 evaluable objective > 50% responses were observed 18 (49%). Three are still unmaintained complete remission after 6-9 mo fourth relapsed 13 mo. Myelotoxicity conspicuously uncommon serious toxicity occurred only one patient. Bleomycin has significant activity malignant lymphomas its unique toxic properties make it ideally suited for combined use other standard agents singly previously treated patients, particularly those marrow depression.